Semax: mechanisms of neuroprotection

In studying the mechanisms of neuroprotection Semax in brain acute focal ischemia patients Semax was appointed at doses of 12 mg / day of moderate severity in stroke and 18 mg / day in severe stroke within 5 days; Criteria for inclusion of patients in the study, methods and schemes of clinical observation and standardized therapy were identical presented in the chapter "Semax: efficiency in the carotid ischemic stroke."

Immuno-biochemical study included determining the concentration of the inflammatory response triggers: IL-1beta, TNF-alpha and IL-8; the main marker of inflammatory reactions - CRP; anti-inflammatory cytokines IL-10 and TGF-beta1; neurotrophins NGF and BDNF; secondary content of LPO products, SOD, cGMP, N-acetylneuraminic acid and neurotransmitter amino acids (glutamate, aspartate, glycine and GABA) in the cerebrospinal fluid; and phencyclidine titer autoantibodies to glutamate-binding protein in the blood serum of NMDA-receptors.